Kornimate/medical-research-clean huggingface dataset:
effects of kinesiotaping on respiratory muscles in very preterm infants

Conditions: Preterm; Premature; Infant, Newborn, Diseases; Respiratory Distress Syndrome; Neonatal Respiratory Distress

Summary: this study aimed to evaluate the effects of kinesio taping on blood gas parameters, respiratory rate, heart rate, oxygen saturation, and pressure limits in preterm infants with rds who are on niv. it is hypothesized that the application of kinesio taping to the chest area of preterm infants may improve respiratory functions and oxygenation at the alveolar level, leading to decreased work of breathing, reduced respiratory rate, and improved neonatal stability by promoting respiratory mechanics and enhancing chest expansion.

very preterm infants are at high risk of respiratory distress syndrome (rds), due to surfactant deficiency and weak respiratory muscles. this condition can contribute to respiratory workload and irregular breathing. this study aimed to investigate the effects of kinesio kinesio-taping technique on the respiratory muscles and diaphragm in very preterm infants undergoing non-invasive. twenty-six preterm infants born before the 32nd gestational week and requiring non-invasive ventilation (niv) support due to rds, were randomly divided into 2 groups as kinesio taping group and control group. kinesio taping was applied by a single physiotherapist to support the intercostal muscles,and, the diaphragm and facilitatory method was used on the respiratory muscles. kinesio taping was removed just after preterm infants were weaned from noninvasive ventilation. blood gas parameters, respiratory rate, heart rate, fio2, fio2/po2 ratio, pip, peep values, and length of stay in niv were recorded before and after 3 days of kt application.

Eligibility criteria:
inclusion criteria: * preterm infants diagnosed with rds * preterm infants born under 32 weeks of gestation exclusion criteria: * sepsis, * necrotizing enterocolitis, * metabolic disease, * severe congenital malformations of the chest and abdominal walls, * congenital heart disease, * major congenital anomalies

Keywords: respiratory distress syndrome preterm infant kinesiotaping pulmonary function
monitoring tissue perfusion in critically ill or high-risk surgical patients

Conditions: High-risk Surgical Patients

Summary: circulatory shock is defined as an imbalance between oxygen supply and/or impaired oxygen use to maintain organ function. with growing evidence of lack of correlation between macro- and micro-circulation, use of "whole body" markers such as blood pressure (bp) or lactates are often insufficient to assess the severity of the oxygen debt and/or tissue hypoperfusion. thus, an approach incorporating tissue-perfusion based endpoints would represent a significant step up to guide optimal resuscitation of critically-ill patients and to reduce complications in high-risk surgery. current monitoring techniques, that complement systemic hemodynamics by focusing on regional perfusion, still lack the required user-friendliness and/or clinical relevance to be routinely used at bedside. therefore, assessment of the adequacy of tissue perfusion and oxygenation is suboptimal, and implementation of the above-mentioned approaches of resuscitation is still a challenge. urethral perfusion is likely to be early and significantly impaired during low-flow states and thus represents a good "candidate" as a surrogate site to assess the perfusion of visceral organs. besides, urethral mucosa can be investigated in a less invasive and simpler manner than "deeper" organs. nowadays, no practical methods or devices are available to monitor perfusion in the pelvic area. thus, recent development of a new monitoring device of urethral perfusion could fill this need and enable enhanced management of patients in intensive care units (icu) and operating rooms (or). the device consists of a modified foley catheter equipped with a photoplethysmographic sensor: the ikorus up probe. the probe will be used by intensivists or anesthesiologists on high-risk surgical patients, i.e. patients with comorbidities undergoing major vascular, thoracic and/or abdominal surgery.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or more, 2. male or female, 3. high-risk surgical patient, 4. life expectancy expected to exceed 72 hours, 5. willing to participate and signed informed consent, 6. affiliation to the french social security system. non inclusion criteria: 1. pregnant or lactating woman, 2. history of recent urological surgery (bladder surgery, prostate surgery...), 3. known stricture or "impossible insertion" last hospitalization, 4. traumatic injury to the lower urinary tract, 5. history of radiotherapy of pelvic or genital area, 6. genital malformation (hypospadias...).
preliminary efficacy and tolerability of ncx-1000 after repeated oral doses in patients with elevated portal pressure

Conditions: Portal Hypertension

Summary: chronic liver diseases are often characterized by portal hypertension, a major complication involving haemodynamic changes due to increased intrahepatic vascular resistance. it has become well established that nitric oxide (no) plays a crucial role in the haemodynamic abnormalities that develop in chronic portal hypertension. ncx-1000 is a no-releasing derivative of ursodeoxycholic acid that would compensate for the defective liver no production in cirrhosis. this study intends to demonstrate the desired therapeutic activity (reduction in portal pressure) in a small number of target patients, to assess the safety and tolerability after repeated oral administrations of ncx-1000, and to get preliminary pharmacokinetic data in this population.

brief summary is complete. study is closed.

Eligibility criteria:
inclusion criteria: * male or non-pregnant female patients of at least 18 years old * hvpg \> 12 mm hg in fasting state on day 1 * free of any other condition (except liver failure) that may alter absorption, distribution, or elimination of drugs exclusion criteria: * oesophageal bleeding in the previous 30 days * known intolerance to ursodeoxycholic acid or nitrates * liver cancer or liver metastasis from another cancer * portal hypertension secondary to venous thrombosis * presence of transjugular intrahepatic portosystemic shunt (tips) * severe liver failure (child-pugh c)

Keywords: liver portal pressure fibrosis nitric oxide
ductus venosus doppler at 16 weeks in monochorial pregnancy

Conditions: Twin Pregnancy, Monochorionic; Pregnancy Followed

Summary: studies shows that the realization of the ductus venosus doppler may improve the screening of the twin-twin transfusion syndrome. in this study, we want to compare the outcome of monochorial pregnancy when this doppler was performed during the ultrasound at16 weeks, and when it wasn't. in order to do that, we will compile past reports (january 2015/ january 2018) of all monochorial pregnancy handled in the hospital of montpellier and kremlin bicêtre. we will establish if the doppler was done or not, if the twin-twin transfusion syndrome appears and the neonatal outcome.


Eligibility criteria:
inclusion criteria: * monochorionic diamniotic twin pregnancies * monochorionicity diagnosed at the first-trimester * follow up and ultrasound realized at the hospital of montpellier or kremlin bicêtre * screening for twin-twin transfusion syndrome achieved exclusion criteria: * missing ultrasound * unregistered outcome of the pregnancy * eclampsia and pre-eclampsia

Keywords: ductus venosus doppler
cardiac sarcoidosis: fdg pet vs. ga-dotanoc pet

Conditions: Sarcoidosis; Cardiac Sarcoidosis

Summary: diagnosing cardiac sarcoidosis has always been challenging: no single imaging modality has proved effective and cardiac biopsies have a very low sensitivity. 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose (fdg) pet preceded by at least 12 hours of fasting has previously been demonstrated to have reasonable accuracy, however, in some patients physiological fdg uptake in the cardiac region hampers correct identification of sarcoid granulomas. gallium ga 68-dotanoc is a conjugate of the somatostatin analogue nal3-octreotide (noc) and gallium ga 68-labeled 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetic acid (dota). we aim to study whether 68ga-dotanoc has superior sensitivity and accuracy than 18-fdg pet in diagnosing cardiac sarcoidosis. in addition, we aim to compare 18-fdg pet preceded by 12 hours fasting with 18-fdg pet during somatostatin blockade of insulin mediated cardiac glucose uptake.

intervention: * study a: subjects with biopsy proven sarcoidosis suspected of cardiac involvement (prone to arrhythmias, cardiac failure, unexplained dyspnea) are studied twice: 1) 18-fdg pet preceded by 12 hours fasting and 2) 18-fdg pet performed during a 2 hour somatostatin blockade (300 microgram/hour)/heparin infusion. * study b: subjects with biopsy proven sarcoidosis suspected of cardiac involvement are studied twice: 1) 18-fdg pet preceded by 12 hours fasting and 2) 68ga-dotanoc pet preceded by at least 6 hours fasting.

Eligibility criteria:
inclusion criteria: * biopsy proven sarcoidosis * suspected cardiac sarcoidosis exclusion criteria: * ischemic heart disease * diabetes * cardiomyopathy

Keywords: sarcoidosis cardiac sarcoidosis 18-fdg pet 68ga-dotanoc pet
exploring the risk factors of otomycosis: a case-control study

Conditions: Otomycosis

Summary: the goal of this observational study is to explore the risk factors of fungal otitis externa in the fungal otitis externa patients the main question it aims to answer is: what behaviors lead to the occurrence of fungal otitis externa? participants will complete a detailed questionnaire survey. if there is a comparison group: researchers will compare the healthy group and the disease group to see if there are any differences.


Eligibility criteria:
inclusion criteria: * symptoms in the case group include tinnitus, ear fullness or blockage, itching, ear pain, discharge, and hearing loss. physical examination reveals the presence of hyphae, scabs, secretions, masses, pus, red skin, erosion, swelling, or granulation in the ear canal. laboratory fungal cultures must be positive. the control group does not have the aforementioned ear symptoms and has not sought medical attention for ear-related symptoms. exclusion criteria: * patients with otitis media, tympanic membrane perforation, or post-radiotherapy.

Keywords: otomycosis predisposing factor
mri in diagnosing and monitoring cidp

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Summary: we want to study whether mri can be useful in diagnosing and monitoring patients with cidp in maintenance treatment with immunoglobulin

chronic inflammatory neuropathies such as chronic inflammatory demyelinating polyradiculoneuropathy (cidp) can be successfully treated with immunoglobulin either intravenously (ivig) or subcutaneously (scig). cidp is diagnosed by electrophysiology which is time-consuming and unpleasant for the patient. new techniques suggest that magnetic resonance imaging (mri) and ultrasound imaging can be used to detect injuries in the peripheral nerves we want to study if mri and ultrasound is able to detect damages in peripheral nerves, nerve roots and plexus in patients with cidp. moreover, we want to compare these findings to healthy matched controls and to see if treatment with immunoglobulin changes findings in mri

Eligibility criteria:
inclusion criteria: cidp patients * age \> 18 and \< 80 years * diagnosed with definite and probable cidp and fulfilling the european federation of neurological sciences/peripheral nerve society (efns/pns) criteria healthy controls * age \> 18 and \< 80 years * no neurological disorders exclusion criteria: * age \ 80 years * contraindications to mri * pregnancy * other cause of neuropathy (incl. pressure neuropathy) * diabetes mellitus

Keywords: subcutaneous immunoglobulin magnetic resonance imaging
sarcopenic obesity: estimation of prevalence and identification of clinical and biological determinants in a population of adult obese patients

Conditions: Obesity

Summary: this project aims first to determine the prevalence of sarcopenia in a population of obese people of extended age group (18-70 years). in a second step, the factors determining and / or predisposing to sarcopenic obesity will be identified as well as plasmatic and urinary biomarkers specific to this phenotype.

collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients. biological collection to identify plasma, serum, genetic, urinary and faecal biomarkers associated with sarcopenic obesity

Eligibility criteria:
inclusion criteria: * age: 18-70 years * sex: men and women * patient followed in clinical nutrition benefiting from a metabolic assessment for optimization of clinical and paraclinical management * patient meeting the criteria of obesity defined by bmi\> 30 kg / m² * major patient with free, informed and signed consent * patient covered by the social security scheme exclusion criteria: * patient with cancer or severe chronic disease (renal failure, respiratory failure, liver failure) * patient with neuromuscular disease * patient with a total inability to walk * minor patient * refusal of the patient to participate in the study * pregnant or lactating women * patient deprived of liberty or under guardianship.

Keywords: obesity sarcopenia
temsirolimus + weekly paclitaxel + carboplatin for recurrent or metastatic head and neck squamous cell cancer (hnscc)

Conditions: Squamous Cell Cancer; Head and Neck Cancer

Summary: the purpose of this study is to find out the good and bad effects that occur when temsirolimus is added to standard chemotherapy with carboplatin and paclitaxel.


Eligibility criteria:
inclusion criteria: * patients must have microscopically confirmed head and neck squamous cell carcinoma (hnscc), recurrent and/or metastatic. * confirmation of hnscc may be obtained from the primary site or metastatic disease. * patients must be at least 18 years of age. * karnofsky performance status must be ≥ 70%. * disease must be measurable by recist criteria. * at least 6 weeks must have elapsed from previous radiation therapy. patient must have recovered from the acute toxic effects of treatment prior to study enrollment. * adequate organ function, as follows: * adequate bone marrow reserve: absolute neutrophil count (anc) ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, and hemoglobin ≥ 9 g/dl. * hepatic: total bilirubin within normal limits (≤ 1.0 mg/dl); alkaline phosphatase (ap), aspartate transaminase (ast) and alanine transaminase (alt) ≤ 1.5 x uln (upper limit of normal) * renal: serum creatinine ≤ 1.3 mg/dl. patients with serum creatinine \> 1.3 mg/dl may be eligible if creatinine clearance (crcl) ≥ 45 ml/min based on the standard cockroft and gault formula. * patients of childbearing potential must have a negative serum pregnancy test within 14 days of treatment. patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug. * patients must sign an informed consent document. exclusion criteria: * previous exposure to temsirolimus or other mtor inhibitors * more than 2 prior cytotoxic regimens in the recurrent/metastatic disease setting * history of any brain metastases * patients who require concomitant medications that are metabolized by hepatic cyp3a4, due to potential drug-drug interaction with temsirolimus * patients with known active interstitial pneumonitis * active infection or serious underlying medical condition that would impair the patient's ability to receive protocol treatment. * women who are pregnant or lactating * other active malignancy, other than indolent malignancies which the investigator determines are unlikely to interfere with treatment and safety analysis * diagnosis of nasopharyngeal cancer is excluded. * patients with multifocal peripheral sensory alterations or paresthesias (including tingling) interfering with function, per patient report (example: activities of daily living) * therapeutic anticoagulation with coumadin (warfarin) * hypertriglyceridemia ≥ grade 2 (ctcae version 3.0). * impaired lung function: o2 saturation 88% or less at rest on room air by pulse oximetry. if o2 saturation is ≤ 88% at rest, further pulmonary function tests (pfts) should be ordered to confirm normal pulmonary function and eligibility.

Keywords: paclitaxel carboplatin temsirolimus head and neck recurrent and/or metastatic 09-131
maintenance treatment of bipolar depression

Conditions: Bipolar Disorder; Depression

Summary: this study will compare two different antidepressant treatment regimens to determine which is more effective in reducing symptoms of bipolar depression.

depression is a serious condition that is often difficult to diagnosis and treat. bipolar disorder-related depression is especially complex because of the presence of mania symptoms. lamotrigine and divalproex are commonly prescribed medications for depression. however, their effectiveness in treating bipolar depression has not been thoroughly evaluated. studies have shown that combining lamotrigine with another antidepressant may be more effective in reducing depressive symptoms than lamotrigine alone. this study will provide participants with either lamotrigine alone or in combination with divalproex and will determine which regimen is more effective in reducing symptoms of bipolar depression. participants will be randomly assigned to a daily regimen of either lamotrigine and divalproex or lamotrigine and placebo for 8 months. participants will be assessed at study entry, at two unspecified times during the study, and at the end of the study. during each assessment, participants will undergo a brief interview and complete a questionnaire about their depressive symptoms, any physical manifestations of their depression, and their overall level of functioning in daily activities.

Eligibility criteria:
inclusion criteria: * diagnosis of bipolar disorder i or ii * experiencing symptoms of depression at study entry or have experienced symptoms of depression within 6 months prior to study entry * willing to use acceptable methods of contraception * parent or guardian willing to provide informed consent, if applicable exclusion criteria: * history of liver disease * history of substance abuse * previous treatment with lamotrigine or divalproex * lamotrigine or divalproex intolerance

Keywords: lamotrigine divalproex antidepressant
mindfulness-based stress reduction for metro nashville public school employees

Conditions: Self-compassion; Burnout; Stress; Anxiety; Depression

Summary: stress, anxiety, and depression are common symptoms among public school teachers. public school teachers are among the top professions reporting stress, anxiety, and depression. the causes are multifactorial and include work-related demands, challenges with students, limited resources, and compassion fatigue. because of this, teachers are at risk of burnout and leaving or changing their profession. the covid-19 pandemic has had a considerable impact on teachers due to disruptions in usual education delivery and ability to support students. recent reports show poorer mental health and decreases in physical activity in teachers since the onset of the pandemic. effective and implementable strategies are urgently needed to address poor mental health and to foster positive health characteristics in this population. mindfulness programs decrease feelings of stress, anxiety, and emotional exhaustion. additionally, mindfulness can improve self-compassion, which may be an important mediating factor in a teacher population. prior work has shown an inverse relationship between self-compassion and burnout. currently, there are few studies investigating whether building self-compassion can reduce burnout in public school teachers. the investigators will explore therelationship between participation in a mindfulness-based stress reduction (mbsr) course and changes in burnout, self-compassion, and other whole person health measures in an educator population. the overall objective of this open pilot study is to examine the feasibility and acceptability of an 8-week remote, group-based mbsr program delivered over zoom for metro nashville public schools (mnps) personnel reporting elevated stress, anxiety, and/or depressive symptoms. our pilot study results will contribute to the evidence on mbsr in a public-school employee population and inform strategies to optimize implementation of our remote mbsr program within the vanderbilt health at mnps system.


Eligibility criteria:
inclusion criteria: * working certificated metro nashville public schools (mnps) employees who self-report stress, anxiety, and/or depressive symptoms exclusion criteria: * unable to commit to the weekly mbsr schedule * have taken the mbsr course previously * participants who do not have reliable home internet

Keywords: burnout self-compassion
different regimens of vitamin d in treatment of children with chronic liver disease

Conditions: Chronic Liver Disease and Cirrhosis

Summary: the primary aim is to assess the efficacy of two different vitamin d regimes in the treatment of vitamin d deficiency in children with chronic liver disease. the secondary aim is to evaluate the effect of vitamin d on liver fibrosis utilizing fibroscan..

• in this study, the investigators are going to find out the optimum regimen to be used for effective treatment of vitamin d deficiency in those patients and to study the effect of vitamin d treatment on liver fibrosis. vitamin d is a hormone involved in the regulation of mineral homeostasis. it protects skeletal integrity and modulates cell growth and differentiation . it is lipid soluble in nature and interacts with vitamin d receptors and regulates the expression of more than 200 genes, mostly involved in apoptosis, cell growth, and cell differentiation . fibroscan: as a non-invasive imaging study for measuring liver cirrhosis by transducer probe-induced elastic share wave that propagates through liver tissue to measure its velocity. it is a promising noninvasive method for detection of cirrhosis in patients with chronic liver disease. therefore, fibroscan can be used regarding the decision of treatment and follow-up of patients with cirrhosis for screening and detection of the complications . in our study the investigators will assess liver fibrosis before and after vitamin d therapy using fibroscan. group a: who received stoss parenteral vitamin d therapy (200.000 iu) once followed by 600 iu/ day orally (equivalent to rda as maintenance). group b: who received 50.000 iu/ week vitamin d orally for four weeks followed by the maintenance dose. the total duration of therapy was 6 months in both groups .

Eligibility criteria:
inclusion criteria: children below the age of 18 with chronic liver disease. exclusion criteria: * patients with concomitant renal affection. * patients who are on anticonvulsant therapy. * patients who lost follow up * patients refuse to participate at any time throughout the study period. * non-compliant patients for more than 50% of time.

Keywords: vitamin d fibroscan